Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

NCT01594437
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
TCN-202, Placebo
Biological
Lead sponsor
Theraclone Sciences, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 18, 2026, 8:14 AM EDT
Enrolling by invitation Phase 2 Interventional

TRACK-TBI Precision Medicine Part 3 - Option II

NCT06790095
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Cyclosporine (CsA), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
San Francisco, California • Pittsburgh, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

NCT01151046
View directory record Official record
Conditions
Her2 Negative Breast Cancer Patients
Interventions
MM-121, Placebo, Exemestane
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Anaheim, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

NCT03866577
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Biological: M254, Placebo, Intravenous immunoglobulin (IVIg)
Biological · Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Whittier, California • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering

NCT03370562
View directory record Official record
Conditions
Shivering, Nausea and Vomiting, Postoperative
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

NCT04677829
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
PNT001, %5 dextrose for infusion
Biological
Lead sponsor
Pinteon Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 1 Interventional

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

NCT01677572
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 90 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 4 Interventional Results available

Double-Blind Placebo-Controlled CIN Trial

NCT02467075
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Iopamidol 300 (Contrast), Placebo (Normal Saline)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 1 Interventional

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

NCT01366001
View directory record Official record
Conditions
Cocaine Abuse
Interventions
ALKS 33-BUP, ALKS 33, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

NCT01162889
View directory record Official record
Conditions
Healthy
Interventions
Placebo SC Injection, ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion, Placebo IV Infusion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT05526391
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Placebo, TAK-341
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

NCT03801252
View directory record Official record
Conditions
Obesity, Induction of Labor Affected Fetus / Newborn
Interventions
Cefazolin, Placebo, Azithromycin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT01075048
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Tivantinib, Placebo, Cetuximab, Irinotecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 18, 2026, 8:14 AM EDT
Not listed Phase 1 Interventional

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

NCT00265278
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Modafinil
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Red Blood Cell ATP Release and Vascular Function in Humans

NCT03404843
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Fasudil Hydrochloride, Saline
Drug · Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 18, 2026, 8:14 AM EDT
Active, not recruiting Phase 3 Interventional

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715
View directory record Official record
Conditions
Breast Cancer; HER2-positive; Metastatic
Interventions
Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

NCT02435433
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Ramucirumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 18, 2026, 8:14 AM EDT
Withdrawn Phase 2 Interventional

NRX-1074 in Early Course Schizophrenia

NCT02603458
View directory record Official record
Conditions
Schizophrenia
Interventions
NRX-1074, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 18, 2026, 8:14 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

NCT01756950
View directory record Official record
Conditions
Influenza
Interventions
2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 3 Interventional Results available

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419558
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 18, 2026, 8:14 AM EDT
Withdrawn Phase 4 Interventional

A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis

NCT02465138
View directory record Official record
Conditions
Pancreatitis
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

NCT03622008
View directory record Official record
Conditions
Antibiotics Causing Adverse Effects in Therapeutic Use
Interventions
FEP-TAZ 4 g, Placebo
Drug · Other
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 18, 2026, 8:14 AM EDT